Physician profile
John P Minni
NPI 1144303009
$1,385,124.03
in general payments reported to CMS, 2019-2025
31 companies · $328K in 2025
The $328K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190K · 2020: $96K · 2021: $134K · 2022: $155K · 2023: $238K · 2024: $245K · 2025: $328K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700K · Consulting Fee: $34K · Travel and Lodging: $27K · Honoraria: $25K · Food and Beverage: $24K · Education: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $699,967.75 |
| Consulting Fee | $34,459.18 |
| Travel and Lodging | $26,599.08 |
| Honoraria | $24,830.87 |
| Food and Beverage | $24,307.83 |
| Education | $509.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $226,800.26 | 2019-2025 | Tremfya |
| Abbvie INC. | $198,721.94 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $162,202.07 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $147,228.44 | 2019-2025 | Dupixent |
| Ucb, INC. | $143,846.45 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $96,012.48 | 2019-2025 | |
| Amgen INC. | $77,119.85 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $67,060.66 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Novartis Pharmaceuticals Corporation | $59,495.16 | 2019-2025 | |
| Incyte Corporation | $51,476.16 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $51,434.04 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $36,575.96 | 2019-2025 | Adbry, Anzupgo |
| Organon LLC | $27,203.63 | 2025 | Vtama |
| Celgene Corporation | $19,994.31 | 2019-2024 | Sotyktu |
| Lilly USA, LLC | $10,484.04 | 2022-2025 | Ebglyss, Taltz, Olumiant |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,214.26 | 2019-2025 | |
| Dermavant Sciences, INC. | $2,960.97 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $503.74 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $222.11 | 2019-2025 | Odomzo, Blu-U |
| Sanofi-Aventis U.S. LLC | $119.16 | 2019-2022 | |
| Almirall LLC | $93.69 | 2024-2025 | Klisyri |
| Dermira, INC. | $66.30 | 2019-2020 | |
| Genentech USA, INC. | $64.75 | 2019 | |
| Mayne Pharma Commercial LLC | $52.58 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.87 | 2023 | Cyltezo |
| Verrica Pharmaceuticals INC. | $24.14 | 2024 | Ycanth |
| Smith+Nephew, INC. | $23.70 | 2025 | Collagenase Santyl |
| Mylan Institutional INC. | $21.98 | 2023 | |
| Biofrontera INC. | $21.12 | 2025 | Ameluz |
| Horizon Therapeutics Plc | $19.47 | 2020 | |
| Vyne Pharmaceuticals INC. | $16.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Minni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.